• Globally regarded soft-tissue sarcoma therapy has been approved by Medsafe for New Zealand patients
• YONDELIS^® (trabectedin) demonstrates 45% reduction in risk of disease progression or death versus dacarbazine^[1]

SINGAPORE and AUCKLAND, New Zealand, Feb. 17, 2023 /PRNewswire/ -- Independent biopharmaceutical company Specialised...